Background: Psoriasis is a common chronic cell-mediated inflammatory skin disease with a strong impact on patient's quality of life, attitude, daily physical and social activities. Nanosilicon, the smallest form of silicon, showed good results in the treatment of irritated skin with an anti-inflammatory and antioxidant effect. Objectives: To assess the efficacy, tolerability and safety of nanosilicon spray in mild plaque psoriasis involving sensitive areas. Methods: Fifty patients with a body surface area <35% were enrolled into a prospective open label clinical study. Patients were treated for 12 weeks with a 3-4 times a day nanosilicon topical spray application. Efficacy and safety were assessed during the therapy and during a 3-month follow up period. Results: The study demonstrated a high clinical remission rate which progressively increased throughout therapy (8% at week 2, 34.1% at week 6 and 56.8% at week 12). No serious adverse events were reported. Conclusions: The study suggests that nanosilicon spray, applied three to four times a day, is an effective topical treatment for mild plaque psoriasia involving less than 35% of the body surface and sensitive areas.
|Number of pages||3|
|Journal||Journal of Plastic Dermatology|
|Publication status||Published - Sep 2008|
- Plaque psoriasis
- Sensitive areas
ASJC Scopus subject areas